In FRONTIER 2, JNJ-2113 maintained high rates of skin clearance through 52 weeks in adults with moderate-to-severe plaque PsO. In the five JNJ-2113 treatment groups, as measured by the Psoriasis Area and Severity Index (PASI), response rates were maintained from Week 16 to Week 52, with ...
Pediatric patients weighing 20 kg to <50 kg should take 20 mg of apremilast twice daily and children weighing at least 50 kg should take 30 mg twice daily. Apremilast (Otezla; Amgen Inc) is currently available in the US for the treatment of moderate to severe plaque psoriasis among children...
SOTYKTU® (deucravacitinib) is an oral prescription medicine, TYK2 inhibitor, and once-daily pill used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills or treatment using ultraviolet (UV) light. P
Patients with psoriasis are prone to develop a severe form of COVID-19 due to comorbidities and the intake of immunosuppressive drugs.4 These patients often are hesitant to receive the vaccine without an expert opinion. COVID-19 vaccines are considered to increase tumor necrosis facto...
In conclusion, the development of Wells' syndrome and Oxford–AstraZeneca COVID-19 vaccination may be related, with delayed-type hypersensitivity reaction as a possible mechanism. We believe that this rare case will broaden the understanding of Wells' syndrome and raise awareness of the cutaneous ...
Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A ...
COVID-19 vaccinesCORONAVIRUS diseasesPSORIATIC arthritisdoi:10.1111/jdv.18032G. PaviaL. GargiuloF. SpinelliJ. AvaglianoM. ValentiR. G. BorroniA. CostanzoA. NarcisiJohn Wiley & Sons, Ltd.Journal of the European Academy of Dermatology and Venereology: JEADV...
Methods: We longitudinally analyzed 152 patients with plaque psoriasis, 86 of whom received two doses of inactivated COVID‐19 vaccine (either BBIBP‐CorV or CoronaVac). Comparisons were made between patients undergoing treatment with biologics (TNF‐ α inhibitors or IL‐17A inhibitors) or ...
COVID-19BIOTHERAPYMEDICAL personnelPSORIASISThe coronavirus disease 2019 (COVID), caused by severe acute respiratory syndrome coronavirus 2 (SARS銆 V infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the...
Most patients experienced mild COVID-19 symptoms; 3 required hospitalization due to dyspnoea and hypoxia. At the time of infection, 80% had received at least one dose of mRNA vaccine. CONCLUSION. Our findings suggest that patients receiving biologic therapy for psoriasis did not exhibit a higher...